Introduction: Immunotherapy with checkpoint inhibitors gains a major role in bladder cancer. Because of the treatment’s immune modulatory effects, patients may develop hepatitis. Hepatitis B was an exclusion criterion in clinical trials that investigated nivolumab. Therefore, its effects and risk of hepatitis B reactivation in nivolumab are not clinically investigated in renal cell carcinoma patients with hepatitis B. Case report: In this case report, we presented a metastatic renal cell carcinoma patient who was treated with anti-viral treatment for hepatitis reactivation caused by previous sunitinib therapy. After progression, nivolumab was commenced and the patient was closely monitored with hepatic function tests. Management and outcome: Nivolumab was well tolerated and no treatment-related adverse effect occurred. Hepatitis or viral hepatitis reactivation was not detected. Discussion: This case supports the safety of nivolumab in patients with renal cell carcinoma and viral hepatitis.
Objective: The reactivation rate of chronic hepatitis B virus infection in cancer patients and chemotherapy regimens thought to be associated with hepatitis reactivation were investigated. Patients and Methods: In all, 3,890 cancer patients were included in this study. Mortality rates, chemotherapy regimens, cancer types, number of positive hepatitis serology and reactivation rates were obtained. Results: Only 354 patients had positive hepatitis serology results (HBsAg+). Twenty-four patients (6.7%) with HBsAg positive serology had reactivation. In patients with hepatitis reactivation, the rates of usage of 5-fluorouracil (5-FU), cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine were found to be significantly higher than corresponding rates in patients with positive hepatitis serology results but without hepatitis reactivation (p < 0.05 for all). Conclusion: Increased reactivation rates were detected with usage of 5-FU, cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine.
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders in which flow cytometry plays a limited yet evolving role in diagnosis. Recent studies have identified CD36 coefficient of variation (CV) as a potential marker of dyserythropoiesis. This study aimed to validate the diagnostic utility of CD36 CV in a local cohort, establish control-based cutoff values, and assess the added value of CD36 CV when integrated into the Ogata score for improved detection of lower-risk MDS. In this retrospective study, 82 patients who underwent bone marrow aspiration for unexplained cytopenia were analyzed using multiparametric flow cytometry, cytogenetics, and morphological assessment. CD36 CV was measured from erythroid precursors, and diagnostic thresholds were determined based on the distribution of values in the control group. Diagnostic models included CD36 CV alone, a combined binary model with Ogata score, and an expanded five-point scoring system. CD36 CV values were numerically higher in MDS patients (mean 75.81) compared to controls (mean 65.84), though not statistically significant (p=0.099). For low-risk MDS, the 75th percentage cutoff yielded 60% sensitivity and 80% specificity. Integration of CD36 CV into the Ogata score improved specificity from 33.3% to 80% at a ≥3-point threshold, with an AUC of 0.754 (p=0.003). Models using higher cutoffs demonstrated lower sensitivity. Incorporating CD36 CV into flow cytometric evaluation enhances diagnostic specificity for lowerrisk MDS without requiring additional antibody panels. This locally validated marker may improve diagnostic accuracy when combined with myelomonocytic immunophenotyping. Standardization across institutions remains necessary for broader applicability.
PURPOSE: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are clinically significant in patients with cancer, as chemotherapy can trigger viral reactivation, leading to liver failure, treatment interruption, or death. Despite this risk, routine viral screening in patients with solid tumors remains inconsistent across institutions and guidelines. The purpose is to determine the frequency of viral screening and the prevalence of HBV, HCV, and HIV infections—and to assess the rate of viral reactivation—in a large cohort of newly diagnosed adult patients with cancer receiving chemotherapy. MATERIALS AND METHODS: A retrospective, multicenter cohort study was conducted across 15 oncology centers in Turkey. Data from 15,942 adults with solid tumors receiving parenteral chemotherapy between January 2018 and December 2022 were analyzed. Patients with primary liver cancer or those receiving non-immunosuppressive therapies were excluded. RESULTS: Among 15,942 patients (median age, 58 years [range, 16-94]; 51.4% male), hepatitis B surface antigen (HBsAg) testing was performed in 90.3%, anti-HCV in 71.7%, and anti-HIV in 64.0%. HBV infection was identified in 4.5% (n = 645), with only 42.9% receiving antiviral prophylaxis. HBV reactivation occurred in 4.0% of HBsAg-positive patients (n = 26). Anti-HCV positivity was found in 0.4% (n = 46), of whom 17.4% had detectable HCV RNA and received treatment. HIV infection was rare (0.06%; n = 6), and no cases of viral reactivation were observed. CONCLUSION: This large multicenter study highlights persistent gaps in viral screening and prophylaxis among patients with solid tumors. Despite lower HBV reactivation rates—likely due to partial prophylaxis—preventable complications still occurred. Despite increases in vaccination and prophylaxis, reactivation rates remain a significant problem. Standardized national protocols for prechemotherapy viral screening and timely antiviral therapy are essential to improve patient safety and treatment outcomes.